News Home

Is OptiNose Inc (OPTN) a Winner in the Drug Manufacturers - Specialty & Generic Industry?

Thursday, May 06, 2021 11:57 AM | InvestorsObserver Analysts
Is OptiNose Inc (OPTN) a Winner in the Drug Manufacturers - Specialty & Generic Industry?

OptiNose Inc (OPTN) is near the top in its industry group according to InvestorsObserver. OPTN gets an overall rating of 38. That means it scores higher than 38 percent of stocks. OptiNose Inc gets a 80 rank in the Drug Manufacturers - Specialty & Generic industry. Drug Manufacturers - Specialty & Generic is number 143 out of 148 industries.

Overall Score - 38
OPTN has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on OPTN!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 38 would rank higher than 38 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With OptiNose Inc Stock Today?

OptiNose Inc (OPTN) stock is unchanged 0% while the S&P 500 has risen 0.37% as of 11:51 AM on Thursday, May 6. OPTN is unchanged $0.00 from the previous closing price of $3.23 on volume of 253,962 shares. Over the past year the S&P 500 has risen 46.85% while OPTN is lower by -25.40%. OPTN lost -$1.94 per share the over the last 12 months.

Click Here to get the full Stock Score Report on OptiNose Inc (OPTN) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App